Evogene Ltd. (EVGN) AI Stock Analysis

Evogene Ltd. is a computational biology company focused on product discovery and development across agriculture, human health, and industrial applications. Its core Computational Predictive Biology (CPB) platform integrates biological insights with big data and artificial intelligence to discover microbes, small molecules, and genetic elements. The Agriculture segment develops seed traits, agricultural chemicals, and biologicals for crops like corn, soybean, and cotton. The Industrial Applications segment develops advanced castor bean seeds as sustainable industrial feedstocks, while the Human Health segment targets microbiome-based therapeutics for immuno-oncology, gastrointestinal disorders, and antimicrobial resistance. Founded in 1999 and based in Rehovot, Israel, Evogene maintains strategic collaborations with BASF SE, Corteva, and Bayer.

Evogene generated revenue of $930,000 in FY2021, $1.7M in FY2022, $3.0M in FY2023, and $5.6M in FY2024 before revenue declined 30.9% to $3.9M in FY2025. Between FY2020 and FY2025, its 5-year revenue CAGR was 29.9%. Gross margin shifted from 17.5% in FY2021 to 57.3% in FY2024, but dropped to -6.3% in FY2025. The company recorded an operating margin of -364.2% and a net loss of -$8.5M in FY2025, improving from a net loss of -$27.8M in FY2021. For the trailing twelve months ended June 30, 2026, revenue stood at $1.7M with an operating margin of -606.6% and diluted EPS of -$1.50, as quarterly revenue dropped 60.7% year-over-year.

As of June 30, 2026, Evogene held $9.4M in cash and short-term investments against total debt of $2.1M, yielding net cash of $7.2M and total assets of $13.4M. Its current ratio stood at 3.57, though shareholders' equity was negative at -$3.3M. In FY2025, operating cash flow was -$13.5M, free cash flow was -$13.6M, and capital expenditures were $135,000. Over a 5-year period, the company's share count changed -70.4%.

At a last close of $0.39 on October 16, 2026, Evogene had a market capitalization of $6.1M and an enterprise value of $379,738. Its price-to-sales multiple was 3.7x, below the 4.1x median of its US-listed Healthcare peers. Its EV-to-revenue was 0.2x and price-to-book was 4.7x. Over the 1-year period, EVGN fell 69.5%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, EVGN fell 98.5% compared to an 83.0% gain for the S&P 500.

One analyst covers Evogene, issuing 1 Strong Buy rating with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $2.15, which is 451.3% above the last close of $0.39. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.4M and EPS of -$1.10. For the following fiscal year, 1 analyst estimates revenue of $2.6M and EPS of -$0.60. Evogene beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 19, 2026.

This page is an AI-written research summary of Evogene Ltd. (EVGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EVGN income statement, EVGN balance sheet, EVGN key metrics, EVGN analyst forecast, EVGN chart. See the EVGN stock overview for the latest quote and news.